Downstream Process Development for Lentiviral Vectors with Adherent Cell Culture Production

Scroll Down

Lentiviral vectors (LVV) are commonly used as an efficient and safe tool to deliver a transgene into dividing and nondividing cells, enabling long-term gene expression.

Production methods must be capable of making large quantities of high-quality functional LVV in an efficient and cost-effective way, but most current cGMP LVV production processes lack the use of sterile filter due to the low stability of lentiviral vectors. The result of which is depletion of precious final vector product on microbiological safety testing or requirement of multiple GMP
batches.

In this fact sheet, Genezen evaluates two different commercially available sterile filters and two different buffer compositions that can be incorporated into the process of LVV production. Our aim was to establish a scalable, fast and robust downstream processing with a sterile filter to maximize final recovery of lentiviral vectors.

Download our ‘Downstream process development for lentiviral vectors’ fact sheet by completing the form on the right.

You may also be interested in...

Genezen Enters Licensing Agreement with CSL…

February 21, 2024 – Genezen, a leading cell and gene therapy...

Read more

Bringing Therapies to Life with Multi-Vector…

Rapid expansion in biotechnology platforms and advancement in genetic editing technologies...

Read more

LVV Approaches to Pseudotyping and Plasmid…

As cell and gene therapies continue to provide unprecedented advancements in...

Read more

Genezen Announces the Appointment of Steven…

BOSTON, MA and FISHERS, IN. – March 13, 2023 – Genezen,...

Read more